A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Innoviva, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 378,300 shares of INVA stock, worth $6.73 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
378,300
Previous 357,200 5.91%
Holding current value
$6.73 Million
Previous $5.86 Million 24.63%
% of portfolio
0.02%
Previous 0.01%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$16.33 - $20.04 $344,562 - $422,844
21,100 Added 5.91%
378,300 $7.3 Million
Q2 2024

Aug 14, 2024

SELL
$14.4 - $16.4 $704,160 - $801,959
-48,900 Reduced 12.04%
357,200 $5.86 Million
Q1 2024

May 15, 2024

BUY
$14.56 - $16.78 $2.84 Million - $3.27 Million
195,100 Added 92.46%
406,100 $6.19 Million
Q4 2023

Feb 14, 2024

SELL
$12.32 - $16.27 $193,424 - $255,439
-15,700 Reduced 6.93%
211,000 $3.38 Million
Q3 2023

Nov 14, 2023

BUY
$12.37 - $13.89 $509,643 - $572,268
41,200 Added 22.21%
226,700 $2.94 Million
Q2 2023

Aug 14, 2023

BUY
$11.39 - $13.72 $763,130 - $919,240
67,000 Added 56.54%
185,500 $2.36 Million
Q1 2023

May 15, 2023

SELL
$10.73 - $13.6 $1.57 Million - $1.99 Million
-146,100 Reduced 55.22%
118,500 $1.33 Million
Q4 2022

Feb 14, 2023

BUY
$11.8 - $13.78 $1.49 Million - $1.74 Million
126,500 Added 91.6%
264,600 $3.51 Million
Q3 2022

Nov 14, 2022

SELL
$11.61 - $15.22 $3.93 Million - $5.15 Million
-338,100 Reduced 71.0%
138,100 $1.6 Million
Q2 2022

Aug 15, 2022

SELL
$14.32 - $19.88 $1.24 Million - $1.72 Million
-86,300 Reduced 15.34%
476,200 $7.03 Million
Q1 2022

May 16, 2022

BUY
$15.39 - $20.25 $5.51 Million - $7.25 Million
357,900 Added 174.93%
562,500 $10.9 Million
Q4 2021

Feb 14, 2022

BUY
$15.91 - $18.72 $1.76 Million - $2.07 Million
110,400 Added 117.2%
204,600 $3.53 Million
Q3 2021

Nov 15, 2021

BUY
$13.06 - $17.24 $1.23 Million - $1.62 Million
94,200 New
94,200 $1.57 Million
Q3 2020

Nov 16, 2020

SELL
$10.33 - $14.49 $502,389 - $704,706
-48,634 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$11.49 - $15.26 $238,992 - $317,408
20,800 Added 74.73%
48,634 $680,000
Q1 2020

May 15, 2020

SELL
$8.11 - $15.23 $298,448 - $560,464
-36,800 Reduced 56.94%
27,834 $327,000
Q4 2019

Feb 14, 2020

SELL
$10.28 - $14.38 $429,354 - $600,595
-41,766 Reduced 39.25%
64,634 $915,000
Q3 2019

Nov 14, 2019

SELL
$10.05 - $14.55 $872,681 - $1.26 Million
-86,834 Reduced 44.94%
106,400 $1.12 Million
Q2 2019

Aug 14, 2019

SELL
$13.1 - $14.95 $740,150 - $844,675
-56,500 Reduced 22.62%
193,234 $2.81 Million
Q1 2019

May 15, 2019

SELL
$13.69 - $20.06 $335,405 - $491,469
-24,500 Reduced 8.93%
249,734 $3.5 Million
Q4 2018

Feb 14, 2019

BUY
$13.96 - $18.26 $1.25 Million - $1.64 Million
89,600 Added 48.53%
274,234 $4.79 Million
Q3 2018

Nov 14, 2018

SELL
$13.63 - $15.7 $576,085 - $663,576
-42,266 Reduced 18.63%
184,634 $2.81 Million
Q2 2018

Aug 14, 2018

BUY
$13.44 - $17.59 $1.09 Million - $1.42 Million
80,966 Added 55.48%
226,900 $3.13 Million
Q1 2018

May 15, 2018

BUY
$13.8 - $16.99 $1.02 Million - $1.25 Million
73,800 Added 102.31%
145,934 $2.43 Million
Q4 2017

Feb 14, 2018

BUY
$11.73 - $14.75 $470,373 - $591,475
40,100 Added 125.18%
72,134 $1.02 Million
Q3 2017

Nov 14, 2017

BUY
$12.06 - $14.12 $386,330 - $452,320
32,034
32,034 $452,000

Others Institutions Holding INVA

About Innoviva, Inc.


  • Ticker INVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,706,000
  • Market Cap $1.24B
  • Description
  • Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...
More about INVA
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.